基于氟嘧啶的辅助化疗对R0切除术后胆道癌的疗效。
The efficacy of fluoropyrimidine-based adjuvant chemotherapy on biliary tract cancer after R0 resection.
作者信息
Kim Young Saing, Jeong Chi-Young, Song Haa-Na, Kim Tae Hyo, Kim Hong Jun, Lee Young-Joon, Hong Soon Chan
机构信息
Division of Hematology and Oncology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, 405-706, South Korea.
Department of Surgery, Institute of Health Sciences, Gyeongsang National University Hospital, Gyeongsang National University School of Medicine, 79 Gangnam-ro, Jinju, 660-702, South Korea.
出版信息
Chin J Cancer. 2017 Jan 13;36(1):9. doi: 10.1186/s40880-017-0182-y.
BACKGROUND
The optimal treatment strategy for biliary tract cancer (BTC) after curative-intent resection remains controversial. The purpose of this study was to evaluate the efficacy of fluoropyrimidine-based adjuvant chemotherapy for BTC patients undergoing microscopically margin-negative (R0) resection.
METHODS
We retrospectively analyzed the clinical data of BTC patients who underwent curative-intent R0 resection. Patients were eligible if they received either fluoropyrimidine-based adjuvant chemotherapy or observation after R0 resection.
RESULTS
A total of 153 patients were included. In the entire patient cohort, no significant differences were observed in 5-year overall survival (OS) rates (48.4% vs. 39.6%, P = 0.439) or 3-year recurrence-free survival (RFS) rates (49.1% vs. 39.5%, P = 0.299) between patients who received fluoropyrimidine-based adjuvant chemotherapy or observation. However, for patients with stages II and III BTC, chemotherapy significantly improved 5-year OS rate (52.4% vs. 35.6%, P = 0.002) and 3-year RFS rate (55.5% vs. 39.1%, P = 0.021) compared with observation.
CONCLUSION
Fluoropyrimidine-based adjuvant chemotherapy may prolong the survival of patients with stages II and III BTC after R0 resection.
背景
根治性切除术后胆管癌（BTC）的最佳治疗策略仍存在争议。本研究的目的是评估氟嘧啶类辅助化疗对接受显微镜下切缘阴性（R0）切除的BTC患者的疗效。
方法
我们回顾性分析了接受根治性R0切除的BTC患者的临床资料。如果患者在R0切除后接受氟嘧啶类辅助化疗或观察，则符合纳入标准。
结果
共纳入153例患者。在整个患者队列中，接受氟嘧啶类辅助化疗或观察的患者之间，5年总生存率（OS）（48.4%对39.6%，P = 0.439）或3年无复发生存率（RFS）（49.1%对39.5%，P = 0.299）无显著差异。然而，对于II期和III期BTC患者，与观察相比，化疗显著提高了5年OS率（52.4%对35.6%，P = 0.002）和3年RFS率（55.5%对39.1%，P = 0.021）。
结论
氟嘧啶类辅助化疗可能会延长II期和III期BTC患者R0切除后的生存期。
Zotero 插件